Atherosclerotic Cardiovascular Disease Clinical Trials in Beijing, Beijing Municipality
4 recruitingBeijing, Beijing Municipality, China
Showing 1–4 of 4 trials
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled774 locationsNCT07037433
Recruiting
Phase 3
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
Atherosclerotic Cardiovascular Disease
Fujian Shengdi Pharmaceutical Co., Ltd.9,262 enrolled1 locationNCT07551492
Recruiting
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
Amgen7,000 enrolled90 locationsNCT06295679
Recruiting
Not Applicable
LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)
Older PatientsAtherosclerotic Cardiovascular DiseaseLDL Cholesterol
China National Center for Cardiovascular Diseases4,200 enrolled1 locationNCT05765370